TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20430594

Group type: EXPERIMENTAL
Intervention: Low Lithium levels (<0.6 mmol/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medium Lithium levels (0.6-0.79 mmol/L)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low Olanzapine doses (<10mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher Olanzapine doses (10-20mg/day)
Number of subjects: 0
Study: 17269594

Group type: EXPERIMENTAL
Intervention: Maxacalcitol
Number of subjects: 31

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 31
Study: 16236142

Group type: EXPERIMENTAL
Intervention: Intravenous corticosteroid therapy (500 mg intravenous methylprednisolone daily)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Oral corticosteroid therapy (1 mg/kg oral prednisolone daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Intravenous corticosteroid therapy
Number of subjects: 65
Study: 12043317

Group type: EXPERIMENTAL
Intervention: Patients with overweight (BMI > 26 kg/m2)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (hypertensives with normal weight)
Number of subjects: 31
Study: 10207780

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg, Amoxycillin 1.0 g, Metronidazole 400 mg (12 h post-treatment)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated group (0 h)
Number of subjects: 28
Study: 8563457

Group type: EXPERIMENTAL
Intervention: Midodrine (alpha-receptor agonist)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Disopyramide
Number of subjects: 1
Study: 19256157

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 1122828

Group type: EXPERIMENTAL
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) for six months, followed by monthly vinblastine injections.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) with additional prophylactic radiotherapy.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) without radiotherapy.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) with reinduction treatment.
Number of subjects: 204
Study: 31107710

Group type: EXPERIMENTAL
Intervention: Fovea‐sparing internal limiting membrane peeling (Group S)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Observation only (Group C)
Number of subjects: 36
Study: 31476701

Group type: EXPERIMENTAL
Intervention: Complex karyotype (CK)
Number of subjects: 644

Group type: COMPARATOR
Intervention: No complex karyotype (CK)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Patients with aberrations of TP53 and ATM
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Complex karyotype (CK) in female and older CLL patients
Number of subjects: 644
Study: 28478481

Group type: EXPERIMENTAL
Intervention: Combination of ω-3 fatty acids and nano-curcumin
Number of subjects: 74

Group type: COMPARATOR
Intervention: ω-3 fatty acids alone
Number of subjects: 74

Group type: COMPARATOR
Intervention: nano-curcumin alone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 25159605

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy (TLH) group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Transvaginal hysterectomy (TVH) group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Transabdominal hysterectomy (TAH) group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Modified lithotomy position (TLH group)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Conventional lithotomy position (TVH group)
Number of subjects: 99
Study: 22661646

Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 592
Study: 21275850

Group type: EXPERIMENTAL
Intervention: RAC (7.5 mg over 1 hour)
Number of subjects: 99

Group type: COMPARATOR
Intervention: LEV (3.75 mg over 1 hour)
Number of subjects: 99

Group type: COMPARATOR
Intervention: RAC and LEV
Number of subjects: 99
Study: 20110023

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 642

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study: 16901950

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT), 40 sessions
Number of subjects: 85

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 85
Study: 15136378

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg (400 microg/d) plus Zafirlukast 20 mg bid
Number of subjects: 49

Group type: COMPARATOR
Intervention: Budesonide 600 microg bid (1,200 microg/d)
Number of subjects: 49
Study: 11091168

Group type: EXPERIMENTAL
Intervention: Low-dose citrate anticoagulation (60 IU heparin/kg body weight as initial bolus; 1:40 ACD‐A: blood as perfusion)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standard anticoagulation regimen (20 IU heparin/kg bolus; 1:20 ACD‐A as perfusion)
Number of subjects: 5
Study: 9135702

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (PD, 120 mg, orally)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PD plus exercise
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GHRP-6 (100 micrograms, i.v.)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: GHRP-6 plus exercise
Number of subjects: 11
Study: 8445463

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate in physiologic saline
Number of subjects: 121

Group type: COMPARATOR
Intervention: USP physiologic saline
Number of subjects: 121
Study: 3524842

Group type: EXPERIMENTAL
Intervention: Nalbuphine (10 mg IV)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Meperidine (50 mg IV)
Number of subjects: 56
Study: 31674216

Group type: EXPERIMENTAL
Intervention: CARE Plus intervention
Number of subjects: 14
Study: 28641022

Group type: EXPERIMENTAL
Intervention: Fitnox (250 mg capsule as single dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 27579772

Group type: EXPERIMENTAL
Intervention: Individual-level plus structural-level intervention (Arm 4)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard of care (Arm 1)
Number of subjects: 136
Study: 24339297

Group type: EXPERIMENTAL
Intervention: Havrix
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Epaxal
Number of subjects: 451
Study: 22498110

Group type: EXPERIMENTAL
Intervention: GSK573719 once-daily doses (62.5-1000 μg)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: GSK573719 twice-daily doses (62.5-250 μg)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Tiotropium (open-label)
Number of subjects: 176
Study: 20054739

Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (1000 mg x day(‐1))
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18617310

Group type: EXPERIMENTAL
Intervention: Videoconferencing instruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face instruction
Number of subjects: 0
Study: 16172619

Group type: EXPERIMENTAL
Intervention: Meal replacements (MR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (C) - structured eating plan
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both MR and C
Number of subjects: 55
Study: 12427189

Group type: EXPERIMENTAL
Intervention: Saline solution administered prior to endotracheal suctioning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suctioning without saline solution
Number of subjects: 20
Study: 10617250

Group type: EXPERIMENTAL
Intervention: E2 1 mg/NGM 90 microg
Number of subjects: 1253

Group type: EXPERIMENTAL
Intervention: E2 1 mg/NGM 30 microg
Number of subjects: 1253

Group type: COMPARATOR
Intervention: E2 1 mg
Number of subjects: 1253
Study: 8950450

Group type: EXPERIMENTAL
Intervention: Biodegradable screws and rods
Number of subjects: 37

Group type: COMPARATOR
Intervention: Metallic implants
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 37
Study: 1958437

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg three times daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control conditions (no nifedipine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 8
Study: 6752331

Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 31880964

Group type: COMPARATOR
Intervention: Ipilimumab 3 mg/kg (ipi3)
Number of subjects: 1670

Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg (ipi10)
Number of subjects: 1670

Group type: EXPERIMENTAL
Intervention: High-Dose Interferon Alfa-2b (HDI)
Number of subjects: 1670
Study: 31299242

Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: 3-dimensional chemoradiation therapy
Number of subjects: 43
Study: 28900520

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physical Examination (PEx)
Number of subjects: 0
Study: 25829048

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (40 mg.kg(‐1))
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 73
Study: 24043677

Group type: EXPERIMENTAL
Intervention: 23 to 32 mm Hg (moderate) compression stocking treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 34 to 46 mm Hg (high) compression stocking treatment
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adherence to treatment
Number of subjects: 100
Study: 21642014

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4
Number of subjects: 439

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 439
Study: 19806184

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02(D)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: RTS,S/AS01(E) and RTS,S/AS02(D)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 3 dose schedules
Number of subjects: 19

Group type: COMPARATOR
Intervention: RTS,S/AS01(E) (0,1,2-month schedule)
Number of subjects: 19

Group type: COMPARATOR
Intervention: RTS,S/AS01(E) and rabies vaccine
Number of subjects: 19
Study: 16276359

Group type: EXPERIMENTAL
Intervention: Health Hunters intervention program focusing on food choice, physical activity, and lifestyle factors
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Health Hunters intervention program
Number of subjects: 40
Study: 15067028

Group type: EXPERIMENTAL
Intervention: FU + leucovorin or FU + levamisole
Number of subjects: 3302

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3302

Group type: EXPERIMENTAL
Intervention: FU-based therapy
Number of subjects: 3302
Study: 11742269

Group type: EXPERIMENTAL
Intervention: Nasal Steroid (NS) - budesonide 400 microg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Specific Immunotherapy (SIT)
Number of subjects: 41
Study: 9338418

Group type: EXPERIMENTAL
Intervention: Haloperidol (Seranace, 0.05 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 15
Study: 7509325

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5-5 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25-50 mg once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3771292

Group type: EXPERIMENTAL
Intervention: Mashed potatoes
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Polished rice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mashed white beans
Number of subjects: 11
Study: 28539351

Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 24
Study: 27280367

Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intention added to standard labeling
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard labeling
Number of subjects: 143
Study: 26643818

Group type: EXPERIMENTAL
Intervention: Group rehabilitation intervention plus usual care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 400
Study: 23716745

Group type: EXPERIMENTAL
Intervention: Standardized patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Manikins
Number of subjects: 80
Study: 20962899

Group type: EXPERIMENTAL
Intervention: Amiloride (10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18947475

Group type: EXPERIMENTAL
Intervention: Rhu‐EPO treatment (250 IU/kg, 3 times weekly for 4 weeks)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rhu‐EPO treatment
Number of subjects: 44
Study: 15714171

Group type: EXPERIMENTAL
Intervention: Low-dose tacrolimus (0.075 mg/kg/day)
Number of subjects: 113

Group type: COMPARATOR
Intervention: High-dose tacrolimus (0.15 mg/kg/day)
Number of subjects: 113
Study: 12842526

Group type: EXPERIMENTAL
Intervention: Total surface-heparinized circuits (Group B, n = 52)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Surface heparinization limited to oxygenator and arterial filter (Group C, n = 56)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (Group A, n = 51)
Number of subjects: 159
Study: 11006056

Group type: EXPERIMENTAL
Intervention: Reminder letter from physician (Group 1)
Number of subjects: 1562

Group type: EXPERIMENTAL
Intervention: Reminder letter from mammography facility (Group 2)
Number of subjects: 1562

Group type: COMPARATOR
Intervention: Control group (Group 3)
Number of subjects: 1562
Study: 11824001

Group type: EXPERIMENTAL
Intervention: Reteplase
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 6010
Study: 1290620

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg, 100 mg, 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 10 mg, 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan (various doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study: 6742256

Group type: EXPERIMENTAL
Intervention: Family-monitored blood pressure cuffs
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Self-monitored blood pressure cuffs
Number of subjects: 396

Group type: COMPARATOR
Intervention: No cuff (control group)
Number of subjects: 396
Study: 30860001

Group type: EXPERIMENTAL
Intervention: Amphetamine extended-release oral suspension (AMPH EROS)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 29739965

Group type: EXPERIMENTAL
Intervention: Healthy Ageing Nutrition Index (HANI) for men
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Healthy Ageing Nutrition Index (HANI) for women
Number of subjects: 1898
Study: 26198386

Group type: EXPERIMENTAL
Intervention: 5-week group-based multidisciplinary programme of task-oriented exercises integrated with cognitive behavioural therapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group-based traditional exercises
Number of subjects: 150
Study: 24460589

Group type: EXPERIMENTAL
Intervention: Ozone application
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Acidulated phosphate fluoride gel
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CPP-ACP-containing material (Tooth Mousse)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Antibacterial bonding agent (Clearfil Protect Bond)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 125
Study: 23251374

Group type: EXPERIMENTAL
Intervention: Severe traumatic bleeding
Number of subjects: 20127

Group type: EXPERIMENTAL
Intervention: Increasing age, decreasing systolic blood pressure, increased respiratory rates, longer central capillary refill times, higher heart rates, lower Glasgow Coma Scores
Number of subjects: 20127

Group type: EXPERIMENTAL
Intervention: Predicted risk of hemorrhage death
Number of subjects: 20127
Study: 19582491

Group type: EXPERIMENTAL
Intervention: Levosimendan (levo)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 600
Study: 18187427

Group type: EXPERIMENTAL
Intervention: Enzymatically processed beta-glucan (Oat-A)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Oat-A
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oat-B
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study: 16238998

Group type: EXPERIMENTAL
Intervention: Ultrasonic dissector
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional methods
Number of subjects: 0
Study: 11904656

Group type: EXPERIMENTAL
Intervention: Prototype face mask (PM)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional masks (CMs)
Number of subjects: 47
Study: 9459240

Group type: EXPERIMENTAL
Intervention: 1 mL of propofol (n = 17)
Number of subjects: 29

Group type: COMPARATOR
Intervention: 1 mL of placebo (n = 12)
Number of subjects: 29
Study: 7658953

Group type: EXPERIMENTAL
Intervention: Brief cardiac rehabilitation lasting 8 weeks
Number of subjects: 187

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 187
Study: 2561144

Group type: EXPERIMENTAL
Intervention: 10 mg benazepril orally once a day for 2 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30183398

Group type: EXPERIMENTAL
Intervention: Vitamin C (VC) supplementation 300 mg per day for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (nothing)
Number of subjects: 0
Study: 28199556

Group type: EXPERIMENTAL
Intervention: Perventricular device closure (PVDC)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Conventional approach (CA)
Number of subjects: 640
Study: 26062187

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking (once a day for 4 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Captopril tablets (12.5 mg, twice a day)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with auricular point sticking
Number of subjects: 90

Group type: COMPARATOR
Intervention: Captopril tablets
Number of subjects: 90
Study: 24135573

Group type: EXPERIMENTAL
Intervention: CYD‐TDV
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 21601287

Group type: COMPARATOR
Intervention: Escitalopram + placebo (MONO condition)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Bupropion-sustained release + escitalopram (COMB condition)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release + mirtazapine (COMB condition)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Combination therapy (Bupropion + Escitalopram or Venlafaxine + Mirtazapine)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Monotherapy (Escitalopram + placebo)
Number of subjects: 605
Study: 19508716

Group type: EXPERIMENTAL
Intervention: Screening Inventory of Psychosocial Problems (SIPP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SIPP usage)
Number of subjects: 0
Study: 16426091

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 14706487

Group type: EXPERIMENTAL
Intervention: Methylphenidate (extended-release version)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Auditory P300 topography (FC2:P4 amplitude ratio >0.5)
Number of subjects: 20
Study: 11990444

Group type: EXPERIMENTAL
Intervention: Combination of EMD and BDX
Number of subjects: 17

Group type: COMPARATOR
Intervention: BDX alone (positive control group)
Number of subjects: 17
Study: 9650731

Group type: EXPERIMENTAL
Intervention: Allithiamin and pantethine supplementation (1 g of allithiamin and 1.8 g of a 55%/45% pantethine/pantothenic acid compound)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study: 7663539

Group type: EXPERIMENTAL
Intervention: 0.05 mg/day estradiol patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1 mg/day estradiol patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.625 mg/day oral conjugated estrogens (Premarin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study: 2486587

Group type: EXPERIMENTAL
Intervention: Warm intravenous crystalloid and prep solutions, extra body covering (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No warm intravenous crystalloid or extra body covering (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 40
Study: 786135

Group type: EXPERIMENTAL
Intervention: Anileridine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 60
Study: 31625262

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Alternative diagnostic approach using HbA1c and fasting plasma glucose
Number of subjects: 988
Study: 28826895

Group type: EXPERIMENTAL
Intervention: Preoperative β-blocker use
Number of subjects: 4076
Study: 25552523

Group type: EXPERIMENTAL
Intervention: Balance rehabilitation group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Functional rehabilitation group
Number of subjects: 130
Study: 23507424

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg daily for four weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg for four weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg for four weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of atorvastatin 40mg / ezetimibe 10mg for four weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Atorvastatin 40mg alone
Number of subjects: 122
Study: 21087317

Group type: EXPERIMENTAL
Intervention: Large (1-2 mm) bovine bone mineral particles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Small (0.25-1 mm) bovine bone mineral particles
Number of subjects: 10

Group type: COMPARATOR
Intervention: Micro-CT measurements
Number of subjects: 10

Group type: COMPARATOR
Intervention: Histomorphometric analysis
Number of subjects: 10